Health & Care for Coronavirus

About Us

The idea of creating this exclusive health portal i.e. HealthAndCare.in, , is inspired through our experiences all around. Tell us about any person on this earth, who has not been a victim of any type of condition or disease. There are various researches taking place all over the world. Experiments and studies are being taken to reveal the hidden causes of dreaded diseases. The aim of all these studies, research and experiments is to come out with the solution of dreaded diseases which have created havoc on this earth.

If you have been to a medical centre or hospital recently, you would have come across people suffering from various illness. Some people who are suffering from cancer are counting their days with their dear ones. There families might be preparing for the improvement of their health. Highly influential people who have good resources at their disposal would have spending lots of money, so that their dear ones may survive.

Diseases are all the creation of manking. For a while we forget that in order to live fruitfully we have to rely on various factors like good lifestyle, taking best nutritious food, saying no to junk food and stress. But who cares?

Through our Health portal www.HealthAndCare.in it will be our endeavour to bring before you Health and nutritious facts along with recent happenings in the field of medical world.

We would be happy to receive your feedbacks from time to time. Keep coming to this portal to get update on recent happenings.

Regards,

Health and Care.in Blog Team

California

CORONAVIRUS VACCINE: WHEN WILL IT BE AVAILABLE?

A new milestone in the frantic quest for a coronavirus vaccine may have been reached. Johnson & Johnson has announced that it will be able to test humans Ad26 SARS-CoV2 by September. What could presage, at best, of a use as of the first weeks of the year 2021.

An agreement between the pharmaceutical company and the Authority for advanced research and development in the biomedical field, has made it possible to release 1 billion euros to give a boost to the work.

Thought since January and tested on animals, the experimental vaccine of the American giant was designed using the same technology as that used in the search for a cure for Ebola. It consists concretely of combining the virus of an ordinary cold incapable of replicating with fragments of Covid-19, in order to provoke an immune response of the patient.

In this tense and exciting race against time, Johnson & Johnson, which aims to eventually produce 1 billion doses, is not alone. All over the planet, companies, laboratories and university institutions are working to demonstrate the efficacy and safety of the remedies hoped for. Another American pharmaceutical company, Moderna, has also started the phase of clinical trials for its vaccine candidate, just like the Chinese group CanSinoBIO.

For their part, Australian researchers have announced that they have made a connection between BCG, well known for being used against tuberculosis, and the coronavirus. Tests are currently being carried out in Australia and should also be carried out in the United Kingdom, the Netherlands and Germany.

NEWS Coronavirus

Abbott to partner with Music Saves Lives to educate youths

The true values of donating blood most people realize only when one of their close family member or close colleague needs, the blood when they become critical through untoward happening. We all know that blood transfusion has been found as a life...

Nerviano Medical Sciences and Servier promises “first-in-class” anticancer drug

Nerviano Medical Sciences (NMS), a research based company based in Italy, known for discovery and development of innovative treatments for cancer and Servier a privately-run research based pharmaceutical company in areas like neurological, cardiovascular,...

Mixing drug Plavix or clopidogrel with aspirin reduces the chance of second stroke

You might perhaps aware that as soon as a person suffers from stroke s/he usually administer with aspirin so as to prevent blood clotting. Despite this sometime a patient may again gets another stroke. The point is providing aspirin after a stroke...

Type 2 diabetes has its warrior – Invokana (canagliflozin) tablets

There has been a lot of buzz around recently regarding new revelation in type 2 diabetes medications. For example, the recent announcement by FDA that it has approved Invokana (canagliflozin) tablets, which enhances glycemic control in adults having...

FDA warns consumers not to eat ProtiDiet High Protein Chocolate Dream Bar

If you have been eating ProtiDiet High Protein Chocolate Dream Bar lately or you intend to purchase it don’t do that. The Food and Drug Administration (FDA) has warned consumers against eating this High Protein Chocolate Dream Bars which has been...

Tamilflu and Relenza control flu but FDA warns to beware from OTC flu drugs

Almost everyone knows how the condition of flu make people sick and in extreme cases cause death. But we must deal with the condition of flu wisely lest scammers could take advantage of the condition and play havoc with our health. According to...

The search for a Covid-19 vaccine is progressing. The first vaccines are tested in the United States and in China. Deadline for results, effectiveness, steps in manufacturing a vaccine ... Decryption.

As the coronavirus epidemic has generalized in France and worldwide, as new cases of contamination and death are confirmed, the National Institutes of Health (NIH) announce the trial of a vaccine (mRNA -1273) against the new coronavirus (SARS-CoV-2) on a volunteer in the United States, Monday, March 16. While China launched its vaccine tests on 108 volunteers on Friday March 20. In France, the Institut Pasteur de Paris and its international network have started 16 simultaneous research projects, including two on vaccines. Their first vaccine prototype tests took place on mice on March 11. "The tests will last a month, a month and a half:mice are vaccinated, then blood is taken regularly to see if they have made antibodies against the vaccine. If they have made antibodies, they are infected with the coronavirus and we can see if they resist, "said one of them on RTL .

Making a vaccine: the big steps

Research teams are advancing on the development of a vaccine against the new coronavirus , but all are unanimous: it will take several months to develop it, so it will not stop the current coronavirus epidemic. Indeed, it is not enough just to find the right formula , the vaccine must then be tested on animals , then on humans and this, at each stage of its manufacturing process. In total, it takes between 6 and 36 months for production, packaging and delivery to the various countries concerned, which in turn will carry out quality checks . "Getting an effective, non-toxic and therefore usable vaccine takes months or even years . This epidemic, however, will perhaps accelerate the development of an active vaccine on coronavirus , that discovered in Wuhan in 2019 or others (as we have already seen 10 and 20 years ago with SARS and the MERS) or at least help optimize the technique and targeting on coronavirus ", comments Mathieu Lafaurie, infectious disease specialist at Saint-Louis hospital.

The effectiveness of a vaccine can only be demonstrated over the long term.

Coronavirus vaccine: how effective?

According to a spokesperson for the service of Pr Didier Raoult, Director of the IHU Méditerranée Infection, it is not reasonable to think that the vaccine is a short-term solution: " The effectiveness of a vaccine cannot be demonstrated only in the long term. People who have been vaccinated and not vaccinated against the virus must have been exposed in a risk zone so that it can be demonstrated that the vaccinated population was less affected than the unvaccinated population. necessarily takes a long time . " Professor Didier Raoult, specialist in emerging tropical infectious diseases at the Marseille Faculty of Medicine, is also conducting research on the effect of molecules including Hydroxychloroquine,used to treat autoimmune diseases like lupus or rheumatoid polyartritis, in order to get treatment faster.

Coronavirus vaccine: when will it be available?

The European Commission has released 10 million euros for the search for a vaccine against the coronavirus and is supporting a project linking 300 hospitals and 900 laboratories. In France, a Task Force has been set up at the Pasteur Institute for the development of vaccines. "We have known the genome sequence of the virus for several weeks, so we can start doing work for the development of a vaccine" said Professor Christophe d'Enfert, scientific director of the Pasteur institute, at France Info . There, researchers decided to start with the measles vaccine(same family of viruses as the SARS-CoV-2 coronavirus) to carry out initial tests. They will assemble the genome of the measles vaccine with a part of that of the coronavirus, to obtain a derivative of vaccine that all the countries of the world know how to produce. Tests on mice began on March 11. "The Institut Pasteur announces a deadline of 18 months [ie the summer of 2021], but it is quite likely that within 18 months, the coronavirus epidemic will no longer exist under these conditions and that, even "There is a new epidemic of Chinese coronavirus in 18 months, the vaccine developed for the current strain no longer works, this is what happened for SARS, " said the spokesman.

Vaccines under test

In the United States, a biotechnology company, Moderna, has been testing since Monday, March 16, its first vaccine against the new coronavirus (SARS-CoV-2), mRNA-1273 , on a voluntary patient. MRNA-1273 is one of the new therapies developed by the biotechnology company. The study, conducted by the US National Institutes of Health (NIH), is in its first phase. It assesses the safety and immunogenicity of three dose levels of mRNA-1273 (25, 100, 250 μg) administered according to a precise vaccination schedule, out of a total of 45 healthy adults enrolled in the study. Results will not be known for 12 to 13 months. The main objective is to assess the safety and reactogenicity of a two-dose mRNA-1273 vaccination schedule. The secondary objective is to assess the immunogenicity of the SARS-CoV-2 S protein.
In China, the first clinical trial has started to test a vaccine on 108 volunteers , all from the city of Wuhan where Covid-19 appeared. Volunteers aged 18 to 60 received their first injection on Friday March 20, followed for the next six months.